Home / Research Articles Hub / Functional Drug Screening in the Era of Precision...
🧬 Medicine & Biology PubMed

Functional Drug Screening in the Era of Precision Medicine.

📅 Published: January 1, 2022 👤 Napoli Giulia C, Figg William D, Chau Cindy H 📖 Frontiers in medicine
AI-Generated Summary

The focus of precision medicine is providing the right treatment to each unique patient. In this review, we discuss the practicality of various 3D drug screening models and each model's ability to capture the patient's tumor microenvironment.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

Key Findings
  • 1 This scientific movement has incited monumental advances in oncology including the approval of effective, targeted agnostic therapies.
  • 2 Yet, precision oncology has focused largely on genomics in the treatment decision making process, and several recent clinical trials demonstrate that genomics is not the only variable to be considered.
  • 3 Drug screening in three dimensional (3D) models, including patient derived organoids, organs on a chip, xenografts, and 3D-bioprinted models provide a functional medicine perspective and necessary complement to genomic testing.
Why It Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source:

Read Full Paper at PubMed
More Medicine & Biology Papers ← Back to Hub 📚 Learning Hub